Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on brain-targeted therapeutics, has provided updates on its Phase IIa feasibility trial for ONP-002, a potential treatment for mild traumatic brain injury (mTBI). The company has dosed nine participants across three active clinical sites in Australia: Alfred Health, Mackay, and Royal Adelaide Hospital. Additionally, Oragenics has received responses from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request briefing package submitted in July 2026. The company is currently reviewing these responses and remains focused on submitting an Investigational New Drug (IND) application by the end of 2026.
In a separate development, Oragenics disclosed that it received a deficiency letter from NYSE American on Aug. 26, 2026, related to stockholders’ equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days from receipt of the letter to submit a plan to regain compliance and intends to do so within the required timeframe. If the plan is accepted, Oragenics would be allowed to maintain its listing during a cure period, subject to periodic review, with a compliance deadline of Feb. 25, 2028.
The advancement of ONP-002 is significant because mTBI, commonly known as concussion, affects millions worldwide and currently has no FDA-approved treatment. ONP-002 is being developed using Oragenics’ proprietary intranasal delivery platform, which aims to deliver therapeutics directly to the brain, potentially offering a first-in-class treatment option. The company’s platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders, underscoring its broad potential impact.
The FDA’s responses to the Type B meeting request are a critical step in the regulatory pathway. A Type B meeting allows companies to discuss specific issues with the FDA, such as clinical trial design or development plans. The company’s planned IND submission by the end of 2026 would enable it to initiate clinical trials in the United States, expanding beyond its current Australian studies. Oragenics has already stated that U.S. Phase 2b trials are planned to follow the Australian Phase IIa trial.
The NYSE American listing deficiency adds a financial compliance burden. The company must address stockholders’ equity concerns to maintain its listing on the exchange. This is a common challenge for clinical-stage biotech firms that often have limited revenue and significant R&D expenses. Failure to regain compliance could lead to delisting, which would impact the company’s ability to raise capital and its stock’s liquidity.
Oragenics is actively working to navigate these regulatory and financial hurdles. The company’s focus on advancing ONP-002 and its intranasal delivery platform could position it to address a significant unmet medical need in neurological care. Investors and stakeholders will be watching closely as the company works toward its IND submission and resolves its NYSE American compliance issues.
For more information on Oragenics, visit the company’s newsroom at https://nnw.fm/OGEN or the company’s website at https://oragenics.com.
